TDMS Study 05099-99 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
SALICYLAZOSULFAPYRIDINE
NTP Experiment-Test: 05099-99 Report: PEIRPT05
Study Type: CHRONIC Date: 05/04/95
Route: GAVAGE Time: 15:02:33
05099/08 -VS- 05099/10 COMPARISON
Facility: SOUTHERN RESEARCH INSTITUTE
Chemical CAS #: 599-79-1
Lock Date: 04/19/94
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25017 Scheduled Sacrifice
25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 001 0 MG/KG
Include 004 RTD 0 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05099-99 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SALICYLAZOSULFAPYRIDINE Date: 05/04/95
Route: GAVAGE Time: 15:02:33
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG RTD
0 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 110
Scheduled Sacrifice 42
Early Deaths
Moribund Sacrifice 5 6
Natural Death 3 4
Dosing Accident 2
Survivors
Terminal Sacrifice 40
Animals Examined Microscopically 50 52
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (47) (51)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Intestine Small, Jejunum (47) (51)
Adenocarcinoma 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Intestine Small, Ileum (47) (51)
Liver (50) (52)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%)
Hepatocellular Carcinoma 12 (24%) 6 (12%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%)
Hepatocellular Adenoma 12 (24%) 13 (25%)
Hepatocellular Adenoma, Multiple 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mesentery (4) (6)
Fat, Sarcoma 1 (17%)
Pancreas (50) (52)
Carcinoma, Metastatic, Lung 1 (2%)
Acinus, Adenoma 1 (2%)
Salivary Glands (50) (52)
Stomach, Forestomach (50) (52)
Squamous Cell Papilloma 3 (6%) 2 (4%)
Stomach, Glandular (50) (52)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05099-99 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SALICYLAZOSULFAPYRIDINE Date: 05/04/95
Route: GAVAGE Time: 15:02:33
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG RTD
0 MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (52)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (52)
Carcinoma, Metastatic, Lung 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (50) (52)
Carcinoma, Metastatic, Lung 1 (2%)
Islets, Pancreatic (50) (52)
Adenoma 1 (2%)
Pituitary Gland (44) (48)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Carcinoma 1 (2%)
Thyroid Gland (50) (52)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
None
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (3) (4)
Mediastinal, Carcinoma, Metastatic,
Harderian Gland 1 (25%)
Lymph Node, Mandibular (50) (51)
Carcinoma, Metastatic, Kidney 1 (2%)
Lymph Node, Mesenteric (50) (52)
Spleen (50) (52)
Hemangiosarcoma 1 (2%) 1 (2%)
Thymus (45) (51)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Lung 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05099-99 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SALICYLAZOSULFAPYRIDINE Date: 05/04/95
Route: GAVAGE Time: 15:02:33
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG RTD
0 MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (52)
Subcutaneous Tissue, Carcinoma, Metastatic,
Harderian Gland 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (52)
Rib, Carcinoma, Metastatic, Harderian Gland 1 (2%)
Skeletal Muscle (2)
Carcinoma, Metastatic, Harderian Gland 1 (50%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (52)
Alveolar/Bronchiolar Adenoma 9 (18%) 10 (19%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (8%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mediastinum, Carcinoma, Metastatic,
Harderian Gland 1 (2%)
Nose (50) (52)
Glands, Carcinoma, Metastatic, Harderian
Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (3)
Adenoma 2 (67%) 2 (67%)
Carcinoma 1 (33%) 1 (33%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05099-99 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SALICYLAZOSULFAPYRIDINE Date: 05/04/95
Route: GAVAGE Time: 15:02:33
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG RTD
0 MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (52)
Cortex, Carcinoma 1 (2%)
Cortex, Carcinoma, Metastatic, Harderian
Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(52)
Lymphoma Malignant 5 (10%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05099-99 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SALICYLAZOSULFAPYRIDINE Date: 05/04/95
Route: GAVAGE Time: 15:02:33
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG RTD
0 MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 37
Total Primary Neoplasms 62 49
Total Animals with Benign Neoplasms 26 26
Total Benign Neoplasms 35 29
Total Animals with Malignant Neoplasms 25 18
Total Malignant Neoplasms 27 20
Total Animals with Metastatic Neoplasms 5 4
Total Metastatic Neoplasm 8 16
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------